Published in Blood Weekly, November 13th, 2003
"To assess the long-term outcome of older patients with Philadelphia- and/or BCR-ABL-positive CML, 199 patients aged greater than or equal to 60 years representing 23% of 856 patients enrolled in the German randomized CML-studies I (interferon alpha (IFN) vs. hydroxyurea (HU) vs. busulfan (BU) and II (IFN+ HU vs. HU alone) were analyzed after a median observation time of 7 years," wrote U. Berger and colleagues, University of Heidelberg.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.